Tanaka F - Search Results

1

Enhanced capture system for mesenchymal‑type circulating tumor cells using a polymeric microfluidic device 'CTC‑Chip' incorporating cell‑surface vimentin.

Kanayama M, Yoneda K, Kuwata T, Mori M, Manabe T, Oyama R, Matsumiya H, Takenaka M, Kuroda K, Ohnaga T, Tanaka F. Kanayama M, et al. Among authors: tanaka f. Oncol Rep. 2024 Nov;52(5):156. doi: 10.3892/or.2024.8815. Epub 2024 Oct 4. Oncol Rep. 2024. PMID: 39364763

2

Circulating tumor cells in pulmonary venous blood of primary lung cancer patients.

Okumura Y, Tanaka F, Yoneda K, Hashimoto M, Takuwa T, Kondo N, Hasegawa S. Okumura Y, et al. Among authors: tanaka f. Ann Thorac Surg. 2009 Jun;87(6):1669-75. doi: 10.1016/j.athoracsur.2009.03.073. Ann Thorac Surg. 2009. PMID: 19463575

3

Circulating tumor cell as a diagnostic marker in primary lung cancer.

Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S. Tanaka F, et al. Clin Cancer Res. 2009 Nov 15;15(22):6980-6. doi: 10.1158/1078-0432.CCR-09-1095. Epub 2009 Nov 3. Clin Cancer Res. 2009. PMID: 19887487

4

Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.

Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Takenoyama M, Yasumoto K, Tanaka F. Hanagiri T, et al. Among authors: tanaka f. Lung Cancer. 2011 Oct;74(1):112-7. doi: 10.1016/j.lungcan.2011.02.001. Epub 2011 Mar 12. Lung Cancer. 2011. PMID: 21397974

5

[Surgical treatment for patients with pulmonary sclerosing hemangioma].

Oka S, Ono K, Kuwata T, Nagata Y, Baba T, Shigematsu Y, Shimokawa H, Uramoto H, Hanagiri T, Tanaka F. Oka S, et al. Among authors: tanaka f. J UOEH. 2011 Mar 1;33(1):41-5. doi: 10.7888/juoeh.33.41. J UOEH. 2011. PMID: 21438340 Japanese.

6

[Management of patients with bronchial foreign bodies].

Takenaka M, Hanagiri T, Ono K, Oka S, Kuwata T, Baba T, Shigematsu Y, Shimokawa H, Nagata Y, Uramoto H, Tanaka F. Takenaka M, et al. Among authors: tanaka f. J UOEH. 2011 Jun 1;33(2):157-61. doi: 10.7888/juoeh.33.157. J UOEH. 2011. PMID: 21702120 Japanese.

7

Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.

Hanagiri T, Ono K, Kuwata T, Takenaka M, Oka S, Chikaishi Y, Shigematsu Y, Nagata Y, Shimokawa H, Nakagawa M, Uramoto H, So T, Tanaka F. Hanagiri T, et al. Among authors: tanaka f. J UOEH. 2011 Sep 1;33(3):205-16. doi: 10.7888/juoeh.33.205. J UOEH. 2011. PMID: 21913377

8

Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer.

Hanagiri T, Takenaka M, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Tanaka F. Hanagiri T, et al. Among authors: tanaka f. J Cardiothorac Surg. 2011 Oct 25;6:144. doi: 10.1186/1749-8090-6-144. J Cardiothorac Surg. 2011. PMID: 22027105 Free PMC article.

9

Results of a surgical resection for patients with stage IV non--small-cell lung cancer.

Hanagiri T, Takenaka M, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Tanaka F. Hanagiri T, et al. Among authors: tanaka f. Clin Lung Cancer. 2012 May;13(3):220-4. doi: 10.1016/j.cllc.2011.05.006. Epub 2011 Dec 3. Clin Lung Cancer. 2012. PMID: 22138036

10

The prognostic significance of HER2 overexpression in non-small cell lung cancer.

Takenaka M, Hanagiri T, Shinohara S, Kuwata T, Chikaishi Y, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Nakagawa M, Uramoto H, So T, Tanaka F. Takenaka M, et al. Among authors: tanaka f. Anticancer Res. 2011 Dec;31(12):4631-6. Anticancer Res. 2011. PMID: 22199341

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,716 results

Search Page

Filters